Rein Therapeutics
RNTX
46 hedge funds and large institutions have $14.8M invested in Rein Therapeutics in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 9 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
18% more capital invested
Capital invested by funds: $12.5M → $14.8M (+$2.29M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.44% less ownership
Funds ownership: 41.08% → 40.65% (-0.44%)
4% less funds holding
Funds holding: 48 → 46 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
+$362K |
| 2 |
PVM
Palogic Value Management
Dallas,
Texas
|
+$223K |
| 3 |
VC
Voss Capital
Houston,
Texas
|
+$179K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$126K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$74.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$139K |
| 2 |
Jane Street
New York
|
-$71.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$68.4K |
| 4 |
Two Sigma Investments
New York
|
-$48.4K |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$38.5K |
RNTX Hedge Fund Activity: Q1 2026 in Review
46 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2026, worth a combined $14.8M — up 18% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RNTX positions and 9 closed out — a net gain of 2 holders — while 14 added to existing stakes and 4 trimmed.
The largest buyer was BIOS Capital Management, adding an estimated $362K. The largest seller was Citadel Advisors, exiting entirely with an estimated $139K sold.
- 46 institutional investors held Rein Therapeutics (RNTX) as of Q1 2026, down from 48 in Q4 2025.
- Funds reported $14.8M of Rein Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
- 11 funds opened new Rein Therapeutics positions in Q1 2026 and 9 closed out, a net change of +2 holders.
- The largest Rein Therapeutics buyer in Q1 2026 was BIOS Capital Management, an estimated $362K added.
- The largest Rein Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $139K sold.
Based on aggregated 13F filings for Q1 2026.